A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: OP-1250|DRUG: Palbociclib
Sponsor: Olema Pharmaceuticals, Inc.
Collaborators: Pfizer